I. Epidemiological profile

<table>
<thead>
<tr>
<th>Population</th>
<th>2013</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>High transmission (&gt;1 case per 1000 population)</td>
<td>7,060,000</td>
<td>7</td>
</tr>
<tr>
<td>Low transmission (0-1 cases per 1000 population)</td>
<td>71,480,000</td>
<td>73</td>
</tr>
<tr>
<td>Total</td>
<td>78,540,000</td>
<td>100</td>
</tr>
</tbody>
</table>

II. Intervention policies and strategies

**Intervention**

<table>
<thead>
<tr>
<th>Policies/strategies</th>
<th>Yes/No</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITN</td>
<td>Yes</td>
<td>2006</td>
</tr>
<tr>
<td>IRS</td>
<td>Yes</td>
<td>2002</td>
</tr>
<tr>
<td>Larval control</td>
<td>Yes</td>
<td>2001</td>
</tr>
<tr>
<td>IPT</td>
<td>N/A</td>
<td>2000</td>
</tr>
<tr>
<td>Treatment</td>
<td>Yes</td>
<td>2003</td>
</tr>
</tbody>
</table>

**Diagnosis**

Patients of all ages should receive diagnostic test | Yes 2004
Malaria diagnosis is free of charge in the public sector | Yes 2003

**Treatment**

ACT is free for all ages in public sector | Yes 2003
Artemisinin-based monotherapies withdrawn | Yes 2003
Single dose of primaquine is used as gametocidal medicine for *P. falciparum* | Yes 2006
Primaquine is used for radical treatment of *P. vivax* | Yes 2007
GIT/PQ test is a requirement before treatment with primaquine | Yes 2011
System monitoring for adverse reactions to antimalarials exists | Yes 2009

III. Financing

**Sources of financing**

- Government
- Global Fund
- World Bank
- USAID/PMI
- WHO/UNICEF
- Others

**Financing by intervention in 2013**

- Antimalarial medicines
- Diagnostic testing
- Insecticide & spraying materials
- Human resources & technical assistance
- Management and other costs

**Cases tested and treated in public sector**

**Test positivity**

- Parasite prevalence (survey)
- Slide positivity rate

**Malaria admissions and deaths**

- Admissions (all species)
- Admissions (*P. vivax*)
- Deaths (all species)
- Deaths (*P. vivax*)

**Impact**

Achieved >75% decrease in case incidence in 2013